What is the appropriate workup and management for a 52-year-old man with erythrocytosis (RBC 6.06 ×10⁶/µL, hematocrit 51.8%)?

Workup and Management for Erythrocytosis (RBC 6.06, Hematocrit 51.8%)

This 52-year-old man requires immediate JAK2 mutation testing (exons 12-15) to exclude polycythemia vera, along with serum erythropoietin level measurement to guide the diagnostic pathway between primary and secondary causes of erythrocytosis 1, 2.

Initial Diagnostic Approach

The hematocrit of 51.8% represents mild erythrocytosis that requires systematic evaluation. The critical first step is distinguishing polycythemia vera (PV) from secondary causes, as this fundamentally changes management and prognosis 3, 4.

Essential First-Line Testing

• JAK2 mutation screening (exons 12-15): This is the single most important test. JAK2 mutations confirm PV and indicate a myeloproliferative neoplasm requiring hematology referral 1, 2
• Serum erythropoietin (EPO) level: This directs the diagnostic pathway:
  • Low/normal EPO suggests primary erythrocytosis (PV or hereditary causes)
  • High EPO suggests secondary erythrocytosis 2, 3
• Historical hematocrit/hemoglobin review: Distinguish longstanding (congenital/hereditary) from acquired erythrocytosis 2, 3

Targeted History and Physical Examination

Look specifically for:

• Cardiovascular symptoms: Headache, visual disturbances, pruritus, erythromelalgia (suggests PV) 4
• Hypoxia risk factors: Smoking history, cardiopulmonary disease, sleep apnea, high-altitude dwelling 2, 5
• Medication review: Testosterone (oral/transdermal/intramuscular), SGLT2 inhibitors, erythropoiesis-stimulating agents 2, 4
• Family history: Hereditary erythrocytosis patterns 2, 3
• Splenomegaly: Physical finding suggesting PV 4
• Renal disease: History suggesting renal artery stenosis or EPO-producing tumors 2, 5

Management Based on Etiology

If JAK2 Mutation Positive (Polycythemia Vera)

Immediate hematology referral is mandatory. For this patient at age 52 without stated thrombosis history (low-risk PV):

• Target hematocrit <45% through phlebotomy 6
• Low-dose aspirin (81-100 mg daily) for vascular symptoms 7, 6
• Cardiovascular risk factor management 6
• Monitor every 3-6 months for thrombosis, bleeding, disease progression 6

Critical caveat: Therapeutic phlebotomy in PV is only indicated when hemoglobin >20 g/dL AND hematocrit >65% WITH symptoms of hyperviscosity (headache, fatigue) and no dehydration 7. This patient's hematocrit of 51.8% does NOT meet criteria for therapeutic phlebotomy—only maintenance phlebotomy to keep hematocrit <45% 6.

If JAK2 Mutation Negative (Secondary or Hereditary Erythrocytosis)

Cytoreductive therapy should be avoided 2, 3. The workup proceeds based on EPO level and clinical context:

High EPO (Secondary Erythrocytosis)

Investigate for:

• Hypoxia: Arterial oxygen saturation, carboxyhemoglobin level (especially smokers), sleep study if indicated 8, 5
• Renal causes: Renal imaging for masses or renal artery stenosis 8, 2
• Drug-induced: Review testosterone, SGLT2 inhibitors, EPO-doping 8, 2

Normal/Low EPO (Consider Hereditary)

If longstanding erythrocytosis with family history:

• P50 measurement: Low P50 suggests high oxygen-affinity hemoglobin variants or 2,3-DPG deficiency 8, 2
• Expanded genetic panel: EPOR, HIF2A, PHD2, VHL, PIEZO1 mutations 2, 3

Management of Secondary Erythrocytosis

• Treat underlying cause (e.g., ACE inhibitors for post-renal transplant erythrocytosis, smoking cessation, CPAP for sleep apnea) 8, 5
• Phlebotomy only for symptom control, NOT based on hematocrit threshold 2, 3
• Target hematocrit ~60% if phlebotomy needed in conditions like COPD or congenital heart disease to balance oxygen delivery against hyperviscosity 8
• Cardiovascular risk optimization and low-dose aspirin are reasonable despite limited evidence 2, 3

Critical Pitfalls to Avoid

1. Do NOT perform routine repeated phlebotomies without clear indication—this causes iron depletion, decreased oxygen-carrying capacity, and increased stroke risk 7

2. Do NOT assume thrombosis risk is equivalent to PV in secondary erythrocytosis—cytoreductive therapy is not indicated 2, 3

3. Do NOT overlook relative polycythemia from volume contraction—this requires hydration, not phlebotomy 2, 4

4. Do NOT miss medication-induced causes, particularly testosterone and increasingly recognized SGLT2 inhibitors 2, 4

5. Ensure iron repletion status is assessed—iron deficiency with erythrocytosis paradoxically increases stroke risk due to rigid, less deformable microcytes 7